CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
396.24MUSDvs all stocks (USD)
Revenue (TTM)
47.01MUSDvs all stocks (USD)
Profit Margin
-157.32%vs Biotechnology peers
Beta
2.09xvs all stocks
52-Week Change
-26.70%vs all stocks
Market Capitalization
396.24MUSDvs all stocks (USD)
Enterprise Value
226.21MUSDvs all stocks (USD)
Forward P/E
-3.43xvs Biotechnology peers
Price to Sales (TTM)
8.43xvs Biotechnology peers
Price to Book (MRQ)
3.76xvs Biotechnology peers
Enterprise to Revenue
4.81xvs Biotechnology peers
Enterprise to EBITDA
-2.79xvs Biotechnology peers
Profit Margin
-157.32%vs Biotechnology peers
Operating Margin
-167.31%vs Biotechnology peers
Return on Assets (TTM)
-23.29%vs Biotechnology peers
Return on Equity (TTM)
-118.82%vs Biotechnology peers
Revenue (TTM)
47.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4640USDUpdated Sep 27, 2026Quarterly Revenue Growth
232.30%vs Biotechnology peers
Gross Profit (TTM)
-37.95MUSDvs all stocks (USD)
EBITDA (TTM)
-81.03MUSDvs all stocks (USD)
Net Income (TTM)
-73.95MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
232.31%vs Biotechnology peers
Operating Cash Flow (TTM)
-119.86MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-44.32MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
40.52MUSDFY2025 · Dec 31, 2025Operating Income
-99.34MUSDvs all stocks (USD)
Pre-tax Income
-160.06MUSDFY2025 · Dec 31, 2025Net Income
-160.06MUSDFY2025 · Dec 31, 2025EBIT
-153.89MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-87.94MUSDFY2025 · Dec 31, 2025Research & Development
89.95MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
49.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.31MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.17MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-160.06MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-158.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
-158.51MUSDDerived from operating cash flow minus capital expenditure. This filing charges 5.28M of depreciation against 338K of capital expenditure, and its own free-cash-flow line reads -165.85M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
149.31MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-160.06MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.72MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.89MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.31MUSDFY2025 · Dec 31, 2025Capital Expenditures
-338.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
139.01MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
138.67MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.87MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
39.98MUSDFY2025 · Dec 31, 2025Shares Outstanding
153.53MSharesUpdated Sep 27, 2026Float Shares
115.49MSharesUpdated Sep 27, 2026Shares Short
29.96MSharesUpdated Sep 27, 2026Short Ratio
11.06daysvs all stocks
Short % of Shares Outstanding
19.54%vs all stocks
% Held by Insiders
0.18%vs all stocks
% Held by Institutions
79.29%vs all stocks
Total Cash (MRQ)
211.64MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.38USDUpdated Sep 27, 2026Total Debt (MRQ)
15.51MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1473xvs Biotechnology peers
Current Ratio (MRQ)
3.19xvs Biotechnology peers
Book Value per Share (MRQ)
0.6860USDUpdated Sep 27, 2026Total Assets
186.53MUSDvs all stocks (USD)
Total Current Assets
163.90MUSDFY2025 · Dec 31, 2025Total Liabilities
159.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
113.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.25MUSDFY2025 · Dec 31, 2025Cash Equivalents
146.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
146.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Receivable
15.18MUSDFY2025 · Dec 31, 2025Accounts Payable
2.60MUSDFY2025 · Dec 31, 2025Short-term Debt
6.03MUSDFY2025 · Dec 31, 2025Deferred Revenue
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt
12.07MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.81MUSDFY2025 · Dec 31, 2025Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.63BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
27.29MUSDvs all stocks (USD)
52-Week Low
1.66USDUpdated Sep 27, 202652-Week High
4.54USDUpdated Sep 27, 202652-Week Change
-26.70%vs all stocks
Beta
2.09xvs all stocks
50-Day MA
2.87USDUpdated Sep 27, 2026200-Day MA
2.64USDUpdated Sep 27, 2026Avg 10-Day Volume
4.18MSharesUpdated Sep 27, 2026Avg 30-Day Volume
3.23MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.6600USDUpdated Sep 27, 2026Other Income / Expense
-62.86MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 2.32Receivables vs revenue divergence: 2.06
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule